Beyond symptomatology: A comparative analysis of unilateral and bilateral macronodular mild autonomous cortisol secretion
Clinical Endocrinology · 2024
DOI: 10.1111/cen.15109 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Tugba Barlas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Hydrocortisone, Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Objective
To investigate the clinical, laboratory findings and signal intensity index (SII) on magnetic resonance imaging (MRI) of patients with bilateral and unilateral macronodular mild autonomous cortisol secretion (MACS). Patients and Measurements Clinical and laboratory findings of 81 patients with MACS were examined from retrospective records. SII of adenomas and internodular areas were evaluated by MRI. The unilateral group included patients with an adrenal macronodule (≥1 cm) in a single adrenal gland, while the bilateral group included patients with at least one macronodule in both adrenal glands.
Results
In total, 46 patients were in the unilateral (57%), while 35 (43%) patients were in the bilateral groups. The dehydroepiandrosterone sulphate (DHEA‐S) level was lower in the unilateral than in the bilateral group ( p < .001). The presence of type 2 diabetes mellitus (T2DM), glycosylated haemoglobin (HbA1c) and low‐density lipoprotein (LDL) concentrations were higher in the bilateral group ( p < .05). However, no significant difference was detected in terms of adrenocorticotropic hormone (ACTH) and overnight 1 mg dexamethasone suppression test (DST) between the two groups ( p > .05). There was no difference in SII between adenomas within the same patient, as well as between the unilateral and bilateral groups ( p > .05). Logistic regression analysis based on the differentiation between unilateral and bilateral macronodular MACS demonstrated that DHEA‐S, HbA1c and LDL concentrations were associated factors.
Conclusion
DHEA‐S levels may not be as suppressed in patients with bilateral macronodular MACS as compared to those with unilateral adenoma. T2DM and hypercholesterolaemia have a higher frequency in bilateral patients. However, ACTH, overnight 1 mg DST and SII may not provide additional information for differentiation of bilaterality and unilaterality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey.
- Department of Radiology, Gazi University, Faculty of Medicine, Ankara, Turkey.
- Department of Urology, Gazi University, Faculty of Medicine, Ankara, Turkey.
- Department of Pathology, Gazi University, Faculty of Medicine, Ankara, Turkey.
Zitieren
APA
Barlas, T., Gultekin, I. I., Altintop, S. E., Cindil, E., Yalcin, M. M., Cerit, E. T., Sozen, T. S., Poyraz, A., Altinova, A. E., Toruner, F. B., Karakoc, M. A., & Akturk, M. (2024). Beyond symptomatology: A comparative analysis of unilateral and bilateral macronodular mild autonomous cortisol secretion. Clinical Endocrinology. https://doi.org/10.1111/cen.15109
Vancouver
Barlas T, Gultekin II, Altintop SE, Cindil E, Yalcin MM, Cerit ET, et al. Beyond symptomatology: A comparative analysis of unilateral and bilateral macronodular mild autonomous cortisol secretion. Clinical Endocrinology. 2024. doi:10.1111/cen.15109
BibTeX
@article{Barlas2024,
author = {Barlas, Tugba and Gultekin, Isil Imge and Altintop, Sabri Engin and Cindil, Emetullah and Yalcin, Mehmet Muhittin and Cerit, Ethem Turgay and Sozen, Tevfik Sinan and Poyraz, Aylar and Altinova, Alev Eroglu and Toruner, Fusun Balos and Karakoc, Mehmet Ayhan and Akturk, Mujde},
title = {Beyond symptomatology: A comparative analysis of unilateral and bilateral macronodular mild autonomous cortisol secretion},
journal = {Clinical Endocrinology},
year = {2024},
doi = {10.1111/cen.15109}
}
EUVIMED